BRIUMVI Cuts RMS Relapse Rate by 70.8% and Boosts NEDA-3 to 77.9%
A post hoc pooled analysis of 168 highly active RMS patients from ULTIMATE I & II showed BRIUMVI reduced ARR by 70.8% (0.145 vs 0.496) and cut Gd+ T1 lesions by 95.6% over 96 weeks versus teriflunomide. NEDA-3 rates reached 77.9% with BRIUMVI versus 16.4%, highlighting its superior efficacy.
1. Study Design and Patient Population
A post hoc pooled analysis of 168 individuals with highly active relapsing multiple sclerosis from the ULTIMATE I & II trials evaluated BRIUMVI versus teriflunomide over 96 weeks. Highly active disease was defined by at least two relapses in the prior year and one gadolinium-enhancing T1 lesion at baseline.
2. Relapse and MRI Activity Reductions
BRIUMVI achieved an unadjusted annualized relapse rate of 0.145 versus 0.496 for teriflunomide, a 70.8% reduction at Week 96. MRI activity also decreased substantially, with Gd+ T1 lesions cut by 95.6% over 96 weeks and new or enlarging T2 lesions reduced by 91.1%.
3. NEDA-3 Outcomes and Clinical Implications
At Week 12, 29.5% of BRIUMVI patients reached no evidence of disease activity (NEDA-3) versus 10.1% for teriflunomide, rising to 77.9% versus 16.4% over Weeks 24-96. These findings reinforce the potential for early use of high-efficacy therapy in patients with aggressive disease.